NOVAVAX INC (NVAX)       11.05  +0.07 (+0.64%)

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

The FDA's experts voted in favor of annual boosters on Thursday.

3 Great Growth Stocks Down 20% or More to Buy Now

These beaten-down stocks could be poised for major rebounds.

NVAX March 10th Options Begin Trading

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

This Investment Strategy Would Have Reduced Your Novavax Losses by 20% Last Year

If you want to invest in volatile stocks, a certain strategy can minimize your overall risk.

3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023

Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze.

Could Novavax Stock Help You Become a Millionaire?

At such a beaten-down valuation, is the upside for Novavax just too significant to ignore?

Here's the Worst Mistake Novavax Investors Can Make in 2023

Can Novavax still win over the long term?

River Private Wealth announces new round of investment in Novavax, Inc

3 Biotech Stocks Under $15 Worth a Second Look in 2023

All three stocks have promising therapies that could drive revenue in the coming years.

Pfizer (PFE) Stock Falls on Analyst Downgrade

Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock.

2 Down-on-Their-Luck Stocks That Could Go Parabolic

Any bit of good news could send these stocks soaring.

If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today

The stock has gone on a wild ride over the past few years.

First Week of NVAX January 2025 Options Trading

Don't Blame the Bear Market for This Growth Stock's Jaw-Dropping Sell-Off

Novavax stock would likely have fallen in 2022 even in a bull market.

With This Big Transition Ahead, Is Novavax a Buy?

Novavax stock sank 92% last year.

COVID-19 public health emergency extended by HHS, possibly for final time (NYSE:PFE)

The COVID-19 public health emergency, in place since January 2020, has again been renewed, HHS Secretary Xavier Becerra said.

2 Biotechs Making Waves With A Single Product in their Pipeline

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Nasdaq Bear Market: 3 Remarkable Growth Stocks That Can Double Your Money in 18 Months

These innovative growth stocks have the tailwinds necessary to deliver triple-digit returns for their shareholders by mid-2024.

Notable Monday Option Activity: SIG, JNJ, NVAX

NVAX Stock Alert: What to Know as Novavax Names New CEO

Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.

Why Is Ocugen (OCGN) Stock Up Today?

Ocugen is hoping its Indian-made inactivated Covid-19 shot can provide a low-cost boost for those previously given MRNA-based vaccines.

Novavax hires new CEO as Stanley Erck to retire this month (NASDAQ:NVAX)

Novavax (NVAX) said on Monday its Chief Executive Officer Stanley Erck will retire from his position on January 23, and will be succeeded by John Jacobs. The company said Erck, who...

Is Novavax Stock a Bargain After Falling More Than 90% From Its High?

Could the biotech be the ultimate contrarian buy of 2023?

How 'Covid Darling' Pfizer Became A 'Show Me' Story For 2023

Sales of Paxlovid and Comirnaty are expected to continue declining this year and next.

7 Sensational Stocks That Can Double Your Money in 2023

Triple-digit returns could be just a click away from the buy button.

Noteworthy Friday Option Activity: APPS, NVAX, GFF

2 Growth Stocks to Buy Heading Into 2023

These biotechs are far from having achieved their full potential.

NVAX stock watch as mid-stage trial for COVID-19, flu vaccine combo starts (NASDAQ:NVAX)

Novavax (NVAX) announced Friday the initiation of a Phase 2 trial to evaluate its COVID-19-flu combination ((CIC)) vaccine in Australia and New Zealand. Read the full story here.

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

February 2023 Options Now Available For Novavax (NVAX)

Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the 'Company' or 'No...